Search

Kimberly Ballard

Examiner (ID: 6099, Phone: (571)272-2150 , Office: P/1649 )

Most Active Art Unit
1649
Art Unit(s)
1675, 1649
Total Applications
847
Issued Applications
398
Pending Applications
83
Abandoned Applications
383

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16778053 [patent_doc_number] => 20210115131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1 [patent_app_type] => utility [patent_app_number] => 17/251059 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251059 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/251059
Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1 Jun 12, 2019 Abandoned
Array ( [id] => 16908991 [patent_doc_number] => 11041018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Agglutination of gangliosides for treating alzheimer's disease [patent_app_type] => utility [patent_app_number] => 16/412082 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 41 [patent_no_of_words] => 15832 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16412082 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/412082
Agglutination of gangliosides for treating alzheimer's disease May 13, 2019 Issued
Array ( [id] => 15264673 [patent_doc_number] => 20190381070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke [patent_app_type] => utility [patent_app_number] => 16/409543 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409543 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/409543
Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke May 9, 2019 Abandoned
Array ( [id] => 16992128 [patent_doc_number] => 20210230548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => NATURAL KILLER CELLS ENGINEERED TO EXPRESS CHIMERIC ANTIGEN RECEPTORS WITH IMMUNE CHECKPOINT BLOCKADE [patent_app_type] => utility [patent_app_number] => 17/050775 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050775 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/050775
NATURAL KILLER CELLS ENGINEERED TO EXPRESS CHIMERIC ANTIGEN RECEPTORS WITH IMMUNE CHECKPOINT BLOCKADE May 2, 2019 Pending
Array ( [id] => 15267531 [patent_doc_number] => 20190382499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => PRION PROTEIN ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/399157 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16399157 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/399157
Prion protein antibodies for the treatment of Alzheimer's disease Apr 29, 2019 Issued
Array ( [id] => 17007081 [patent_doc_number] => 20210238242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => A Method For Preparing PHFS-Like Tau Aggregates [patent_app_type] => utility [patent_app_number] => 17/050579 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050579 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/050579
Method for preparing PHFS-like Tau aggregates Apr 28, 2019 Issued
Array ( [id] => 15527245 [patent_doc_number] => 20200055928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => HUMANIZED ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/371464 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371464 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/371464
HUMANIZED ANTIBODY Mar 31, 2019 Abandoned
Array ( [id] => 14929959 [patent_doc_number] => 20190300617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => ERENUMAB COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/372291 [patent_app_country] => US [patent_app_date] => 2019-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16372291 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/372291
Erenumab compositions and uses thereof Mar 31, 2019 Issued
Array ( [id] => 16582861 [patent_doc_number] => 20210017263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => MONOCLONAL ANTIBODY SPECIFICALLY REACTING WITH DUPAN-2 ANTIGEN AND METHOD FOR PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 17/043510 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043510 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/043510
MONOCLONAL ANTIBODY SPECIFICALLY REACTING WITH DUPAN-2 ANTIGEN AND METHOD FOR PRODUCING SAME Mar 28, 2019 Abandoned
Array ( [id] => 14564121 [patent_doc_number] => 20190209667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => METHOD FOR DIAGNOSING AND TREATING DYSAUTONOMIA AND OTHER DYSAUTONOMIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/358979 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358979 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/358979
METHOD FOR DIAGNOSING AND TREATING DYSAUTONOMIA AND OTHER DYSAUTONOMIC CONDITIONS Mar 19, 2019 Abandoned
Array ( [id] => 16832147 [patent_doc_number] => 11008388 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => RGMa binding protein and use thereof [patent_app_type] => utility [patent_app_number] => 16/358657 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18728 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358657 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/358657
RGMa binding protein and use thereof Mar 18, 2019 Issued
Array ( [id] => 17784715 [patent_doc_number] => 11407827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => Prognostic biomarker in cancer [patent_app_type] => utility [patent_app_number] => 16/980600 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 26 [patent_no_of_words] => 11485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980600 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/980600
Prognostic biomarker in cancer Mar 13, 2019 Issued
Array ( [id] => 14746867 [patent_doc_number] => 20190256607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE [patent_app_type] => utility [patent_app_number] => 16/287533 [patent_app_country] => US [patent_app_date] => 2019-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16287533 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/287533
Methods for treating or preventing migraine headache Feb 26, 2019 Issued
Array ( [id] => 17588816 [patent_doc_number] => 11327078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement [patent_app_type] => utility [patent_app_number] => 16/965161 [patent_app_country] => US [patent_app_date] => 2019-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12507 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965161 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/965161
Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement Feb 24, 2019 Issued
Array ( [id] => 14442053 [patent_doc_number] => 20190178899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => HIGH SENSITIVITY IMMUNOASSAYS AND KITS FOR THE DETERMINATION OF PEPTIDES AND PROTEINS OF BIOLOGICAL INTEREST [patent_app_type] => utility [patent_app_number] => 16/282943 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282943 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/282943
HIGH SENSITIVITY IMMUNOASSAYS AND KITS FOR THE DETERMINATION OF PEPTIDES AND PROTEINS OF BIOLOGICAL INTEREST Feb 21, 2019 Pending
Array ( [id] => 14929921 [patent_doc_number] => 20190300598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE [patent_app_type] => utility [patent_app_number] => 16/282205 [patent_app_country] => US [patent_app_date] => 2019-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16282205 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/282205
PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE Feb 20, 2019 Abandoned
Array ( [id] => 17385630 [patent_doc_number] => 20220033482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ALPHA-SYNUCLEIN SINGLE DOMAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/971157 [patent_app_country] => US [patent_app_date] => 2019-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971157 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/971157
Alpha-synuclein single domain antibodies Feb 18, 2019 Issued
Array ( [id] => 15293679 [patent_doc_number] => 20190389975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS [patent_app_type] => utility [patent_app_number] => 16/264343 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264343 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/264343
Methods and compositions for increasing alpha-L-iduronidase activity in the CNS Jan 30, 2019 Issued
Array ( [id] => 16397315 [patent_doc_number] => 20200338173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => DEAD ANTIGEN STIMULATED IMMATURE HETEROGENOUS DENDRITIC CELLS AS THERAPEUTICS FOR DISEASES [patent_app_type] => utility [patent_app_number] => 16/959013 [patent_app_country] => US [patent_app_date] => 2019-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959013 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/959013
Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases Jan 17, 2019 Issued
Array ( [id] => 14649129 [patent_doc_number] => 20190231693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER [patent_app_type] => utility [patent_app_number] => 16/238355 [patent_app_country] => US [patent_app_date] => 2019-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238355 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/238355
LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER Jan 1, 2019 Abandoned
Menu